Concepedia

Different mutants of PSMB5 confer varying bortezomib resistance in T lymphoblastic lymphoma/leukemia cells derived from the Jurkat cell line

Shuqing Lü, Jianmin Yang, Zhilong Chen, Shenglan Gong, Hong Zhou, Xiaoqian Xu, Jianmin Wang

Experimental Hematology · 2009 · 84 citations · 18 references

DOI

Concepts

References

18

A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma

Paul G. Richardson, Bart Barlogie, James R. Berenson et al. · New England Journal of Medicine · 2003 · 2.6K citations · Full text

, , +10

Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma

Paul G. Richardson, Pieter Sonneveld, Michael W. Schuster et al. · New England Journal of Medicine · 2005 · 2.5K citations · Full text

, , +14

The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells.

Teru Hideshima, Paul G. Richardson, D Chauhan et al. · PubMed · 2001 · 1.5K citations

, , +17

Phase II Study of Proteasome Inhibitor Bortezomib in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma

André Goy, Anas Younes, Peter McLaughlin et al. · Journal of Clinical Oncology · 2004 · 527 citations · Full text

, , +15

Crystal Structure of the Boronic Acid-Based Proteasome Inhibitor Bortezomib in Complex with the Yeast 20S Proteasome

M. Groll, Celia R. Berkers, Hidde L. Ploegh et al. · Structure · 2006 · 471 citations · Full text

, , +16